CBG is the abbreviation for cannabigerol, a non-psychoactive cannabinoid found in cannabis plants. More widely known as the “mother cannabinoid,” CBG is believed to be key in the biosynthesis of other cannabinoids such as THC and CBD. Enzymes within the plant break down CBGa, or cannabigerolic acid, into either THC, CBD, or CBC — cannabichromene — as the plant grows, leaving a mature plant with only small trace quantities of CBG. This is part of the reason why researchers have studied CBG less than its more well-known counterparts.
Despite its limited presence, CBG continues to generate interest because of its promising therapeutic benefits. It interacts with both the CB1 and CB2 receptors that are involved in a number of functions within the body, including pain perception, mood regulation, and inflammation. According to some initial studies, this phytocannabinoid might be used for glaucoma, inflammatory bowel disease, and even some types of cancer.
CBG is not psychoactive, meaning that it won’t provide the “high” associated with THC. This makes it appealing for those looking for therapeutic relief without the mind-altering effects of THC. CBG is consumed in the form of oil, tincture, capsule, or as an active ingredient in full-spectrum CBD products.
As cannabis research continues, CBG will be one of the more significant compounds to make its mark in the world of medicinal cannabis.
